FDA Launches Device Trial Participation Snapshots Pilot Program
核心洞察
The FDA's CDRH (搜索) has initiated a pilot program mirroring the CDER's drug trials snapshots to enhance transparency in medical device clinical trials.
The program provides key information on clinical trial participants and device performance across diverse groups for newly approved medical devices.
Snapshots are currently available for higher-risk devices approved under original PMA applications from April to July 2024, offering a limited-time view.
The FDA's Center for Devices and Radiological Health (CDRH (搜索)) has launched a pilot program to provide consumers and healthcare professionals with crucial information regarding clinical trials that supported the approval of new medical devices. This initiative mirrors the Center for Drug Evaluation and Research (CDER)'s drug trials snapshots program, aiming to increase transparency and understanding of medical device performance across different patient populations.
The Device Trial Participation Snapshots program addresses key questions about the participants in clinical studies of new medical technology and the available clinical trial information regarding how these devices perform in various demographic groups. These snapshots are currently accessible for higher-risk devices approved under original premarket approval (PMA) applications from April to July 2024. It's important to note that the snapshots provide information available at the time of approval and will not be updated with real-world data over time.
This pilot program aligns with the FDA's ongoing efforts to enhance transparency and promote diversity in clinical trial participation for novel medical products. By providing detailed snapshots of clinical trial data, the FDA aims to empower both consumers and healthcare professionals with the information needed to make informed decisions about medical device usage.
Interested parties can submit comments on the snapshots pilot program via www.Regulations.gov under docket number FDA-2024-N-4561 by January 13, 2025. This feedback will help the FDA evaluate and refine the program to better serve the needs of the public and the healthcare community.